Study of BW-50218 in Healthy Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants

NCT07401472•Shanghai Argo Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Detailed Description

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Capable of providing written informed consent and complying with all study procedures for the duration of the study.
•Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.
•Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
•Male participants with partners of childbearing potential must agree to use effective contraception.

Exclusion Criteria

•Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.
•Recent hospitalization or a significant acute medical event.
•History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
•Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
•Positive test for hepatitis B, hepatitis C, or HIV.

Locations (2)

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Linear Early Fhase Limited

Nedlands, Western Australia, Australia

Key Dates

Start Date

February 25, 2026

Primary Completion Date

June 30, 2027

Completion Date

June 30, 2027

Last Updated

March 5, 2026

Enrollment

ESTIMATED participants

Conditions

Healthy Participants Study

Interventions

BW-50218 Injection

DRUG

Saline (0.9% NaCl)

DRUG

Contacts

Zhi Hua

CONTACT

+86 185 1618 7545 zhi.hua@argobiopharma.com

The Effect of Diathermy Therapy on Isolated Lumbar Extension (ILEX) Training

NCT06852872

Resistance TrainingHealthy Participants Study

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions